Genetic analysis of immunomodulating factors in sporadic Parkinson's disease

J Neural Transm (Vienna). 2000;107(5):553-62. doi: 10.1007/s007020070078.

Abstract

Immunomodulating factors have been shown to play a role in the pathogenesis of Parkinson's disease (PD) by biochemical methods. In order to investigate functionally important genes of the tumor necrosis factor alpha (TNFalpha) pathway we studied the frequency of DNA polymorphisms in the interleukin 6 (IL6), the TNFalpha, and the TNFalpha receptor 1 (TNFR1) genes in 264 sporadic German PD patients and in 183 age and sex matched German healthy controls. Analyzing the TNFalpha-308 polymorphism we found heterozygous individuals carrying alleles 1 and 2 more frequently in patients with a relative risk of 1.56 (p = 0.046, p(c) = 0.13, chi2 = 3.98). In contrast, the frequency of the B/2 haplotype described by the TNFR1-609 and TNFRI+36 polymorphisms was significantly decreased in our PD patients group (p = 0.0097, p(c) = 0.048, chi2 = 6.69) with a relative risk reduced to 0.52. Our results suggest an involvement of immunomodulating factors in the pathogenesis of sporadic PD as revealed by a molecular genetic approach.

MeSH terms

  • Adjuvants, Immunologic / genetics*
  • Aged
  • Alleles
  • Antigens, CD / genetics*
  • Case-Control Studies
  • Chi-Square Distribution
  • Female
  • Genotype
  • Germany
  • Humans
  • Interleukin-6 / genetics
  • Male
  • Middle Aged
  • Parkinson Disease / genetics*
  • Polymorphism, Genetic / genetics*
  • Receptors, Tumor Necrosis Factor / genetics*
  • Receptors, Tumor Necrosis Factor, Type I
  • Tumor Necrosis Factor-alpha / genetics*

Substances

  • Adjuvants, Immunologic
  • Antigens, CD
  • Interleukin-6
  • Receptors, Tumor Necrosis Factor
  • Receptors, Tumor Necrosis Factor, Type I
  • Tumor Necrosis Factor-alpha